Full Breakdown
Roche's Fenebrutinib Shows Promise in Multiple Sclerosis Trials
11/10/2025, 9:25:26 PM
Key Findings from Pivotal Trials
Roche has announced significant results from two pivotal Phase III studies evaluating fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of multiple sclerosis (MS). The first study, FENhance 2, demonstrated that fenebrutinib significantly reduced the annualized relapse rate (ARR) in patients with relapsing multiple sclerosis (RMS) compared to teriflunomide, a drug marketed by Sanofi under the brand name Aubagio. This reduction was observed over a treatment period of at least 96 weeks. Additionally, the FENtrepid study, which assessed fenebrutinib against OCREVUS (ocrelizumab) in primary progressive multiple sclerosis (PPMS), showed that fenebrutinib was non-inferior to OCREVUS in delaying disability progression over at least 120 weeks.
Mechanism of Action
Fenebrutinib targets both B cells and microglia, addressing acute inflammation that leads to relapses and chronic damage contributing to long-term disability. Its design allows it to penetrate the central nervous system (CNS) effectively, which is crucial for treating MS. The drug's high potency and selectivity for BTK are intended to provide a more targeted approach compared to traditional immunosuppressants.
Study Design and Methodology
The FENhance studies involved a total of 1,497 adult patients with RMS, randomized to receive either oral fenebrutinib or teriflunomide. The primary endpoint was the ARR, while secondary endpoints included various measures of confirmed disability progression. The FENtrepid study included 985 patients with PPMS, comparing fenebrutinib to OCREVUS.
Safety and Regulatory Considerations
Roche reported that liver safety data for fenebrutinib was consistent with previous studies, despite earlier concerns that led the U.S. FDA to halt enrollment in one of the trials due to liver injury cases. The company is currently evaluating additional safety data and plans to present comprehensive results at upcoming medical meetings. Full data from the second RMS trial, FENhance 1, is expected in the first half of 2026, after which Roche will consider submitting all findings to regulatory authorities.
Market Implications
Analysts suggest that if fenebrutinib is approved, it could generate over $1 billion in annual sales for Roche. The drug's success in these trials positions it as a potential new treatment option for MS patients, particularly in a market where existing therapies have limitations.
Criticism and Opposition
Despite the promising results, some analysts have raised questions regarding Roche's claims of non-inferiority versus OCREVUS, noting that the study was initially designed to demonstrate superiority. This shift in endpoint has led to scrutiny over the trial's design and the implications for regulatory approval.
What's Next
Roche is set to share detailed data from both pivotal studies at upcoming medical meetings and will await results from the FENhance 1 trial before proceeding with regulatory submissions. The outcomes of these studies will be critical in determining the future of fenebrutinib as a treatment option for multiple sclerosis.
Verbatim Quotes
“Fenebrutinib substantially reduced the number of relapses in RMS and slowed disability progression in PPMS.” — Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer.
“ Liver safety was consistent with previous fenebrutinib studies.” — Roche statement.
“Jefferies analysts said that the success of Roche's regulatory submissions for the drug are critically dependant on full safety and efficacy data from the three studies.” — Jefferies analyst.
“we cannot comment right now on discussions around what we might or might not do in PPMS.” — Levi Garraway, M.D., Ph.D.
